Payment overview · 2025
General Payments
$68.18
4 reported records · 4 companies
Healthcare provider profile · identity verified
Sarath Babu, MD
Allopathic & Osteopathic Physicians|Internal Medicine · EAST BRUNSWICK, NJ · NPI 1992744767
Verified facts
What the public records show
CMS Open Payments records show Sarath Babu, MD received $68.18 in general payments during 2025 across 4 reported records.
Alkermes, Inc. accounted for 31.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Roxybond.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
PROTEGA PHARMACEUTIALS INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ROXYBOND as an associated drug or biological on 2633 records involving 1078 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Roxybond by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $21.17 | 31.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.24 | 23.8% | 1 | 2025 |
| PROTEGA PHARMACEUTIALS INC | Unresolved — no canonical attribution shown | $16.16 | 23.7% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $14.61 | 21.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $68.18 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| ROXYBOND Normalized: roxybond |
Drug | PROTEGA PHARMACEUTIALS INC | $16.16 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $14.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ROXYBOND roxybond |
2025 | Roxybond | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PROTEGA PHARMACEUTIALS INC Exact reporting entity; no affiliate inference |
2025 | ROXYBOND open payments reported associated product |
CMS Open Payments — General Payments 2633 supporting records · 1078 recipient NPIs · example record 1235986235 |
Roxybond · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 1202 | 78 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 647 | 55 |
| Alprazolam | Alprazolam | 434 | 49 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 347 | 27 |
| Methadone Hcl | Methadone Hcl | 306 | 17 |
| Oxycontin | Oxycodone Hcl | 290 | 14 |
| Gabapentin | Gabapentin | 280 | 39 |
| Tramadol Hcl | Tramadol Hcl | 266 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 243 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 173 | 33 |
| Morphine Sulfate Er | Morphine Sulfate | 166 | 11 |
| Diazepam | Diazepam | 157 | 19 |
| Clonazepam | Clonazepam | 153 | 13 |
| Buprenorphine Hcl | Buprenorphine Hcl | 146 | suppressed |
| Losartan Potassium | Losartan Potassium | 129 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 126 | 31 |
| Metformin Hcl | Metformin Hcl | 124 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 114 | 32 |
| Pregabalin | Pregabalin | 105 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 105 | 33 |
| Atorvastatin Calcium | Atorvastatin Calcium | 104 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 103 | 41 |
| Hydromorphone Hcl | Hydromorphone Hcl | 101 | suppressed |
| Fentanyl | Fentanyl | 90 | suppressed |
| Azithromycin | Azithromycin | 79 | 55 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 61 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 57 | 20 |
| Trulicity | Dulaglutide | 56 | suppressed |
| Eliquis | Apixaban | 53 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 14 |
| Xtampza Er | Oxycodone Myristate | 50 | suppressed |
| Amoxicillin | Amoxicillin | 49 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 17 |
| Ibuprofen | Ibuprofen | 47 | 17 |
| Roxybond | Oxycodone Hcl | 45 | suppressed |
| Valsartan | Valsartan | 45 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 44 | suppressed |
| Furosemide | Furosemide | 40 | 16 |
| Methylprednisolone | Methylprednisolone | 40 | 27 |
| Baclofen | Baclofen | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 23 |
| Ozempic | Semaglutide | 38 | 11 |
| Simvastatin | Simvastatin | 38 | suppressed |
| Ondansetron Odt | Ondansetron | 37 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 36 | suppressed |
| Lisinopril | Lisinopril | 36 | 12 |
| Morphine Sulfate | Morphine Sulfate | 36 | suppressed |
| Omeprazole | Omeprazole | 36 | 12 |
| Naproxen | Naproxen | 35 | 17 |
| Trazodone Hcl | Trazodone Hcl | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Glimepiride | Glimepiride | 34 | suppressed |
| Cefdinir | Cefdinir | 31 | 25 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | 12 |
| Atenolol | Atenolol | 30 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 12 |
| Levofloxacin | Levofloxacin | 30 | 22 |
| Percocet | Oxycodone Hcl/Acetaminophen | 30 | suppressed |
| Famotidine | Famotidine | 29 | suppressed |
| Meloxicam | Meloxicam | 29 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Carisoprodol | Carisoprodol | 28 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 28 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Trulance | Plecanatide | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 26 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Nucynta Er | Tapentadol Hcl | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Prednisone | Prednisone | 23 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 22 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 19 | suppressed |
| Testosterone | Testosterone | 19 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Xyosted | Testosterone Enanthate | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | 13 |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 15 | suppressed |
| Buprenorphine | Buprenorphine | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Toprol Xl | Metoprolol Succinate | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $68.18 · 4 records | Alkermes, Inc. | BREZTRI, BRIXADI, ROXYBOND, VIVITROL | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Roxybond play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error